Literature DB >> 22473935

Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies.

Andrea Klein1, Suzanne Lillis, Iulia Munteanu, Mariacristina Scoto, Haiyan Zhou, Ros Quinlivan, Volker Straub, Adnan Y Manzur, Helen Roper, Pierre-Yves Jeannet, Wojtek Rakowicz, David Hilton Jones, Uffe Birk Jensen, Elizabeth Wraige, Natalie Trump, Ulrike Schara, Hanns Lochmuller, Anna Sarkozy, Helen Kingston, Fiona Norwood, Maxwell Damian, Janbernd Kirschner, Cheryl Longman, Mark Roberts, Michaela Auer-Grumbach, Imelda Hughes, Kate Bushby, Caroline Sewry, Stephanie Robb, Stephen Abbs, Heinz Jungbluth, Francesco Muntoni.   

Abstract

Ryanodine receptor 1 (RYR1) mutations are a common cause of congenital myopathies associated with both dominant and recessive inheritance. Histopathological findings frequently feature central cores or multi-minicores, more rarely, type 1 predominance/uniformity, fiber-type disproportion, increased internal nucleation, and fatty and connective tissue. We describe 71 families, 35 associated with dominant RYR1 mutations and 36 with recessive inheritance. Five of the dominant mutations and 35 of the 55 recessive mutations have not been previously reported. Dominant mutations, typically missense, were frequently located in recognized mutational hotspot regions, while recessive mutations were distributed throughout the entire coding sequence. Recessive mutations included nonsense and splice mutations expected to result in reduced RyR1 protein. There was wide clinical variability. As a group, dominant mutations were associated with milder phenotypes; patients with recessive inheritance had earlier onset, more weakness, and functional limitations. Extraocular and bulbar muscle involvement was almost exclusively observed in the recessive group. In conclusion, our study reports a large number of novel RYR1 mutations and indicates that recessive variants are at least as frequent as the dominant ones. Assigning pathogenicity to novel mutations is often difficult, and interpretation of genetic results in the context of clinical, histological, and muscle magnetic resonance imaging findings is essential.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22473935     DOI: 10.1002/humu.22056

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  56 in total

1.  Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of RYR1, CACNA1S and STAC3 variants.

Authors:  Senthilkumar Sadhasivam; Barbara W Brandom; Richard A Henker; John J McAuliffe
Journal:  Pharmacogenomics       Date:  2019-09       Impact factor: 2.533

2.  RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.

Authors:  Paul J Isackson; Jianxin Wang; Mohammad Zia; Paul Spurgeon; Adrian Levesque; Jonathan Bard; Smitha James; Norma Nowak; Tae Keun Lee; Georgirene D Vladutiu
Journal:  Pharmacogenomics       Date:  2018-10-16       Impact factor: 2.533

3.  Bi-allelic expression of the RyR1 p.A4329D mutation decreases muscle strength in slow-twitch muscles in mice.

Authors:  Moran Elbaz; Alexis Ruiz; Sven Nicolay; Chiara Tupini; Christoph Bachmann; Jan Eckhardt; Sofia Benucci; Pawel Pelczar; Susan Treves; Francesco Zorzato
Journal:  J Biol Chem       Date:  2020-06-04       Impact factor: 5.157

4.  Severe Neonatal RYR1 Myopathy With Pathological Features of Congenital Muscular Dystrophy.

Authors:  Daniel C Helbling; David Mendoza; Julie McCarrier; Mark A Vanden Avond; Matthew M Harmelink; Paul E Barkhaus; Donald Basel; Michael W Lawlor
Journal:  J Neuropathol Exp Neurol       Date:  2019-03-01       Impact factor: 3.685

5.  Mouse model of severe recessive RYR1-related myopathy.

Authors:  Stephanie Brennan; Maricela Garcia-Castañeda; Antonio Michelucci; Nesrin Sabha; Sundeep Malik; Linda Groom; Lan Wei LaPierre; James J Dowling; Robert T Dirksen
Journal:  Hum Mol Genet       Date:  2019-09-15       Impact factor: 6.150

6.  A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene.

Authors:  Sissel Løseth; Nicol C Voermans; Torberg Torbergsen; Sue Lillis; Christoffer Jonsrud; Sigurd Lindal; Erik-Jan Kamsteeg; Martin Lammens; Marcus Broman; Gabriele Dekomien; Paul Maddison; Francesco Muntoni; Caroline Sewry; Aleksandar Radunovic; Marianne de Visser; Volker Straub; Baziel van Engelen; Heinz Jungbluth
Journal:  J Neurol       Date:  2013-01-18       Impact factor: 4.849

7.  RYR1 mutations as a cause of ophthalmoplegia, facial weakness, and malignant hyperthermia.

Authors:  Sherin Shaaban; Leigh Ramos-Platt; Floyd H Gilles; Wai-Man Chan; Caroline Andrews; Umberto De Girolami; Joseph Demer; Elizabeth C Engle
Journal:  JAMA Ophthalmol       Date:  2013-12       Impact factor: 7.389

Review 8.  Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.

Authors:  Sheila Riazi; Natalia Kraeva; Philip M Hopkins
Journal:  Anesthesiology       Date:  2018-01       Impact factor: 7.892

9.  Single-channel properties of skeletal muscle ryanodine receptor pore Δ4923FF4924 in two brothers with a lethal form of fetal akinesia.

Authors:  Le Xu; Frederike L Harms; Venkat R Chirasani; Daniel A Pasek; Fanny Kortüm; Peter Meinecke; Nikolay V Dokholyan; Kerstin Kutsche; Gerhard Meissner
Journal:  Cell Calcium       Date:  2020-02-17       Impact factor: 6.817

10.  Structural determinants of skeletal muscle ryanodine receptor gating.

Authors:  Srinivas Ramachandran; Asima Chakraborty; Le Xu; Yingwu Mei; Montserrat Samsó; Nikolay V Dokholyan; Gerhard Meissner
Journal:  J Biol Chem       Date:  2013-01-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.